As of 2025-04-24, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (4,998.48) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -58905.7%.
The range of the Relative Valuation is (3,973.58) - (5,708.35) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.9x - 32.2x | 25.6x |
| Forward P/E multiples | 16.9x - 27.2x | 22.0x |
| Fair Price | (3,973.58) - (5,708.35) | (4,998.48) |
| Upside | -46848.0% - -67257.1% | -58905.7% |
| Date | P/E |